Post-traumatic Stress Disorder Clinical Trial
Official title:
Effects of Treatment of Post-traumatic Stress Disorder on Reduced Recall for Fear Extinction
This preliminary study will examine the differential effects of rTMS on the recall of extinction of conditioned fear in patients suffering from PTSD (post-traumatic stress disorder ) compared with subjects without PTSD but with high risk of relapse.
It is estimated that nearly 70% of individuals will experiment at least once in their life a
traumatic event (eg war, natural disaster, accident or assault). The psychotrauma, whose
symptoms (including revivalism, hypersensitivity to the environment, anxiety, avoidance
behavior), may be sustainable and thus constitute a posttraumatic stress disorder (PTSD).
One characteristic of PTSD can be studied in the laboratory is the lack of recall of
extinction of conditioned fear, caused largely by a lack of induction of hyperactivation in
the prefrontal cortex. Knowing that this hyperactivation may occur in some cases of
remission of symptoms of PTSD, it is possible that the deficit in recall of extinction is
lifted in such cases. This idea is also supported by animal models showing that the
induction of natural or artificial prefrontal hyperactivation facilitates the recall of
extinction. However, no study has yet addressed so far the effects of different treatments
(conventional: pharmacotherapy and psychotherapy, or rTMS: repetitive transcranial magnetic
stimulation) for PTSD, supposed to induce prefrontal hyperactivation and avoid the recall
deficit of extinction of conditioned fear. The persistence of this deficit beyond the
remission of PTSD symptoms could represent a situation with a high risk of relapse.
Objective. Our main objective is to examine performance in recall of extinction of
conditioned fear on the one hand, in patients in remission of PTSD after conventional
treatment and, secondly, in patients who received rTMS at 10 Hz
Population: THIS PRELIMINARY STUDY will include 9 patients with PTSD, 3 individuals in
remission from PTSD, 3 psychotraumatized subjects without secondary PTSD and 3 individuals
without a history of psychotrauma. These groups will be matched for age, sex and
sociocultural level.
Method: All studies will be conducted at the Nice University Hospital. The pre-inclusion
visit (D-7), including different clinical evaluations (MINI-DSM-IV, CAPS, PDI, Hamilton
Depression Scale and Covi Anxiety), will be held at the Emergency Psychiatric Unit (Hospital
Saint-Roch). The study will take place at the Psychiatry University Department and at the
Neurology Exploration Department (Hospital Pasteur), where the subjects will have other
clinical assessments (at D0, D17-D19, D21), the conditioning test and extinction (day 0) and
recall test of extinction (at D21). The fear conditioning (measured by increases in heart
rate and skin conductance) corresponds to presentations coupled with an image and tactile
stimulation (the intensity of which will be chosen by the subject), while sessions of
extinction and extinction recall that correspond to presentations of the image alone
(without tactile stimulation). In addition to these sessions, one third of PTSD patients
will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day), another third
with placebo treatment and one third without treatment. Eventually (D21), two other tests
will indirectly assess prefrontal hyperactivation (emotional Stroop and attentional bias)
and self-questionnaires will be performed in all subjects immediately after the recall of
extinction.
The persistent failure to recall extinction in some individuals in remission from PTSD would
sign the maintenance of prefrontal dysfunction, and therefore a high risk of relapse. The
induction of hyperactivation using prefrontal rTMS at 10 Hz would not only reduce symptoms
of PTSD, but also reduce the risk of recurrence of these symptoms.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04317820 -
Deep Brain Reorienting in Post-traumatic Stress Disorder
|
N/A | |
Completed |
NCT05112003 -
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
|
N/A | |
Recruiting |
NCT04518267 -
Anger and Psychotrauma: Data From Military and Civilians
|
||
Completed |
NCT02502604 -
Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Terminated |
NCT02234687 -
A mGlu2/3 Agonist in the Treatment of PTSD
|
Phase 1 | |
Completed |
NCT01738308 -
The Effects of Healing Touch on Post Operative Pediatric Patients
|
N/A | |
Terminated |
NCT02520726 -
PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims
|
Phase 4 | |
Completed |
NCT02213900 -
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
|
Phase 4 | |
Completed |
NCT01517711 -
Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)
|
Phase 4 | |
Completed |
NCT01437891 -
Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)
|
N/A | |
Completed |
NCT01998100 -
Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01199107 -
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01231711 -
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
|
Phase 1 | |
Completed |
NCT00680524 -
Telephone-based Care for OEF/OIF Veterans With PTSD
|
N/A | |
Completed |
NCT00838006 -
Psychophysiologic Predictors of Post-deployment Mental Health Outcomes
|
N/A | |
Completed |
NCT00348036 -
Group Intervention for Interpersonal Trauma
|
N/A | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00127673 -
Comparison of Two Treatments for Post-Traumatic Stress Disorder
|
Phase 3 | |
Completed |
NCT00158262 -
Effect of Propranolol on Preventing Posttraumatic Stress Disorder
|
Phase 4 |